8-K: Masimo Reports Mixed Q4 and Full-Year 2023 Results, Provides 2024 Guidance

Masimo Corporation announced its fourth quarter and full-year 2023 financial results, showing a mix of revenue performance and providing updated financial guidance for 2024.

Summary

• Masimo's consolidated revenue for the fourth quarter of 2023 was $548.9 million, with healthcare revenue at $339.9 million and non-healthcare revenue at $209.0 million.
• For the full year 2023, consolidated revenue reached $2,048.1 million, including healthcare revenue of $1,275.5 million and non-healthcare revenue of $772.6 million.
• The company reported a GAAP net income per diluted share of $0.63 for Q4 2023 and $1.51 for the full year.
• Non-GAAP net income per diluted share was $1.25 for Q4 2023 and $3.79 for the full year, using an updated definition.
• Masimo shipped 58,500 noninvasive technology boards and instruments in Q4 2023, excluding handheld and fingertip pulse oximeters, and 263,000 for the full year.
• The company's first quarter 2024 revenue is projected to be between $476 million and $501 million, with full-year 2024 revenue guidance between $2,045 million and $2,165 million.
• The full year 2024 non-GAAP operating profit is expected to be between $307 million and $322 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positives like record contract wins and growth in hearables, the overall financial results show a decline in revenue and earnings compared to the previous year. The updated guidance for 2024 is mixed, and there are several risk factors mentioned.

Positives

• Masimo achieved record contract wins in its healthcare business during 2023.
• The hearables business experienced strong growth in 2023.
• The company is well-positioned for 2024 due to a healthy contract backlog and cutting-edge innovations.
• Masimo has received important FDA clearances for innovative new products.
• The company has updated its non-GAAP financial measures to exclude all expenses related to its litigation with Apple, which may provide a clearer view of ongoing performance.

Negatives

• Healthcare revenue decreased by 3.4% in Q4 2023 compared to Q4 2022.
• Non-healthcare revenue decreased by 21.2% in Q4 2023 compared to Q4 2022.
• GAAP operating income decreased from $73.5 million in Q4 2022 to $44.1 million in Q4 2023.
• GAAP net income per diluted share decreased from $0.76 in Q4 2022 to $0.63 in Q4 2023.
• Full year GAAP net income per diluted share decreased from $2.60 in 2022 to $1.51 in 2023.
• Non-GAAP net income per diluted share decreased from $4.87 in 2022 to $3.79 in 2023.

Risks

• The company is dependent on Masimo SET and Masimo rainbow SET products and technologies for substantially all of its revenue.
• There is a risk of intellectual property claims from competitors.
• The markets in which Masimo operates are highly competitive.
• There is a risk of failure to continue developing innovative products and technologies.
• The company faces the risk of lack of acceptance of current or future products and technologies.
• Obtaining regulatory approval for current and future products and technologies is a risk.
• The company faces risks related to global economic and marketplace uncertainties, including the impact of the COVID-19 pandemic.
• There are ongoing litigation and related matters that could impact the company.

Future Outlook

Masimo anticipates revenue between $476 million and $501 million for Q1 2024 and between $2,045 million and $2,165 million for the full year 2024. The company expects non-GAAP operating profit to be between $307 million and $322 million for the full year 2024.

Management Comments

• Joe Kiani, Chairman and CEO, stated that Masimo exited 2023 with growing momentum driven by record contract wins in healthcare, FDA clearances for new products, and strong growth in the hearables business.
• Kiani also noted that Masimo's ability to translate core technologies into products that deliver better outcomes is the engine for long-term growth.
• Kiani believes that with the stabilization of hospital operations and a healthy contract backlog, Masimo is well-positioned for 2024.

Industry Context

The announcement reflects Masimo's position in the medical technology and consumer audio industries. The company's focus on innovative monitoring technologies and expansion into consumer audio through acquisitions like Sound United is a key aspect of its strategy. The results also highlight the challenges of balancing growth in both healthcare and non-healthcare sectors, particularly in a competitive market.

Comparison to Industry Standards

• Masimo's performance is compared to its own historical results, with a focus on year-over-year growth and constant currency adjustments.
• The company's non-GAAP metrics are used to provide a clearer picture of its core operating performance, excluding items like litigation expenses and acquisition costs.
• While specific competitor comparisons are not provided, the document highlights Masimo's leadership in pulse oximetry and its expansion into new markets like hearables and wearables.
• The company's growth in contract value and backlog is a positive indicator, but the decline in revenue in some segments suggests challenges in market conditions or competitive pressures.
• The company's non-GAAP operating margin of 15% for full year 2024 is a key metric to compare against industry peers such as Medtronic, Stryker, and Boston Scientific, which typically have operating margins in the range of 20-30%.

Legal Proceedings

• The company has been engaged in various legal proceedings against Apple since January 2020.
• Masimo has updated its non-GAAP financial measures to exclude all expenses related to its litigation with Apple.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and earnings compared to the previous year.
• Employees may be impacted by the company's performance and strategic changes.
• Customers may benefit from the company's innovative new products and technologies.
• Suppliers may be affected by changes in the company's business operations.
• Creditors may be impacted by the company's financial performance.

Next Steps

• The company will hold a conference call on February 27, 2024, to discuss the financial results.
• Masimo will continue to focus on its strategic growth initiatives, including hearables and wearables.
• The company will work towards achieving its 2024 financial guidance.

Key Dates

Keywords

Masimo, Financial Results, Healthcare, Non-Healthcare, Pulse Oximetry, Hearables, Wearables, FDA Clearances, Non-GAAP, Revenue, Operating Income, Net Income, Earnings Per Share, Financial Guidance